



BULGARIAN
MEDICAL
SOCIETY OF
HEMATOLOGY

ELEVENTH NATIONAL CONGRESS OF HEMATOLOGY AND JOINT EHA-13th BALKAN HEMATOLOGY DAY

October 10-13, 2019, RIU Pravets Resort, Pravets

PROGRAM

October 10, 2019 /Thursday/

Pravets Conference Hall

15:30 – 16:00 Opening Ceremony

SATELLITE SYMPOSIUMS

Moderator: Gueorgui Balatzenko

16:00 – 16:30 Satellite symposium Sobi:

Two years of experience with Efmoroctocog alfa (Elocta) in Bulgaria.

Moderator: Dobrin Konstantinov

Two years of experience in the treatment of patients above 18 years of age with Efmoroctocog alfa (Elocta) in Bulgaria. Toshko Lissichkov

Two years of experience in the treatment of patients with coagulopathies below 18 years of age with Efmoroctocog alfa (Elocta) in Bulgaria. Atanas Banchev

16:30 – 16:45 Satellite symposium Servier:

Oncaspar - our new weapon against ALL Dobrin Konstantinov

Moderator: Zhanet Grudeva-Popova

16:45 – 17:00 Satellite symposium Sanofi Genzyme:

Timely diagnosis of Gaucher disease and benefits of modern oral treatment with Cerdelga. Gergana Tsvetkova

Moderator: Evgueniy Hadjiev

17:00 – 17:15 Satellite symposium Angelini:

Iclusig – where and when?

Results from the 5-years follow up of patients with chronic myeloid leukemia in chronic phase: PACE 5-years follow-up. The place of Iclusig (ponatinib) in the therapy of CML patients.

17:15 – 17:25 Satellite symposium Abbvie:

CLL treatment with Venetoclax - NSHATHD experience Penka Ganeva

17:25 – 17:45 Coffee Break

17:45 – 18:30 Satellite symposium Takeda:

TAKEDA ONCOLOGY - Solutions for therapy of multiple myeloma and CD 30+ lymphomas

Moderator: Zhanet Grudeva-Popova

The Tourmaline MM1 study: oral ixazomib, lenalidomide and dexamethasone in multiple myeloma. Experience with Ixazomib in UMHAT St. Marina, Varna. Ilina Micheva

Guidelines for the treatment of multiple myeloma. Double versus Triple Therapy. Penka Ganeva

Bretuximab vedotin-based first-line regimens for newly diagnosed stage IV cHL patients. A clinical case of CHL, at University Hospital Sv.Georgi, Plovdiv. Emil Spasov

18:30 – 18:55 Satellite symposium Roche – The evolution of treatment in Follicular Lymphoma

Moderator: Julian Rainov

18:55 – 19:00 Bulgarian Society of Oncological Pharmacy. Tzvetanka Valchanova

19:00 – 19:35 Satellite symposium Roche - From big data to clinical practice, Emicizumab addressing challenges in people with hemophilia A.

Moderator: Zhanet Grudeva-Popova

19:40 – 22:00 Welcome Reception /Tera Hall/

**October 11, 2019 /Friday/
EDUCATIONAL PROGRAM
JOINT EHA-BALKAN HEMATOLOGY DAY**

Chairs: Prof John Gribben, President, European Hematology Association (EHA); Prof Gert Ossenkoppele, Chair EHA Education Committee; Prof Gianluca Gaidano, Chair EHA Global Outreach Program Unit; Prof Margarita Guenova, Representative Balkan Societies

Pravets Conference Hall

09:00 – 09:10 Joint EHA – Balkan Hematology Day – Opening

Gert Ossenkoppele, Chair of the EHA Educational Committee

Gianluca Gaidano, Chair EHA Global Outreach Program Unit

Margarita Guenova, Bulgarian Society of Hematology

09:10 – 10:40 Joint EHA – Balkan Hematology Day – Acute Myeloid Leukemia: Session 1

Chairs: Konstanze Döhner, Department of Internal Medicine III, University Hospital of Ulm, Germany; Andrija Bogdanovic, Haematological Section of Serbian Medical Association; Radu Niculescu, Roumanian Society of Hematology

09:10 – 09:55 Diagnostic work-up of AML: State of the art.

Prof. Konstanze Döhner, Department of Internal Medicine III, University Hospital of Ulm, Germany

09:55 – 10:40 AML clinical cases and challenges

Rare AML variants, diagnostic and management challenges – a clinical case.

Charis Matsouka, Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Hellenic Society of Hematology

AML FLT3-ITD case with FLU/MEL conditioning and PTCy – a clinical case.

Zsofia Varady, Bone Marrow Transplant Department, Fundeni Clinical Institute, Bucharest, Romanian Society of Hematology

Concomitant presentation of t-AML and late relapse of multiple myeloma after autologous haematopoietic stem cell transplantation. Viktoria Yankova, National Specialised Hematology Hospital – Sofia, Bulgarian Society of Hematology.

10:40 – 11:00 Coffee Break

11:00 – 12:30 Joint EHA – Balkan Hematology Day – Acute Myeloid Leukemia: Session 2

Chairs: Gert Ossenkoppele, Department of Hematology, Amsterdam University Medical Centers location VUmc, the Netherlands; Arben Ivanaj Albanian Society of Hematology; Maria Pagoni, Hellenic Society of Hematology

11:00 – 11:45 Treatment of AML: State of the art.

Gert Ossenkoppele, Department of Hematology, Amsterdam University Medical Centers location VUmc, the Netherlands

11:45 – 12:30 AML clinical cases and challenges

Treatment of relapsed and refractory elderly AML patients. Inci Alacacioglu, Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkish Society of Hematology

AML Clinical case. Inga Mandac, Department for Hematology, University Hospital "Merkur", Zagreb, Croatian Society of Hematology

AML Clinical case. Oliver Karanfilski, University Clinic for Hematology, Medical Faculty, Skopje, Macedonian Society of Hematology

12:30 – 13:30 The Lake Restaurant

13:30 – 15:10 Joint EHA – Balkan Hematology Day – Acute Lymphoblastic Leukemia: Session 1

Chairs: Rob Pieters, Dutch Childhood Oncology Group, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Dobrin Konstantinov, Bulgarian Society of Hematology; Inga Mandac, Croatian Society of Hematology

13:30 – 14:00 Key-note-lecture: The role of CART19-cells in the treatment of ALL

Julio Delgado, Department of Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

14:00 – 14:45 Treatment of acute lymphoblastic leukemia guided by genetics and minimal residual disease.

Rob Pieters, Dutch Childhood Oncology Group, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands

14:45 – 15:00 ALL clinical cases and challenges

ALL in a child. Nadezhda Yurukova, Clinic of Children's Oncohematology and Transplantation, Queen Johanna University Hospital - ISUL, Sofia, Bulgarian Society of Hematology

15:00 – 15:30 Coffee Break

15:30 – 17:00 Joint EHA – Balkan Hematology Day – Acute Lymphoblastic Leukemia: Session 2

Chairs: Renato Bassan, Division of Hematology, Ospedale dell'Angelo, Mestre, Venice, Italy; Hayri Ozsan, Turkish Society of Hematology; Aferdita Ukimeraj, Kosovo Society of Hematology

15:30 – 16:15 Progress and challenges in adult ALL.

Renato Bassan, Division of Hematology, Ospedale dell'Angelo, Mestre, Venice, Italy

16:15 – 17:00 ALL clinical cases and challenges

TKI in pregnancy. Alma Cili, University of Medicine Tirana, Albanian Society of Hematology

ALL Clinical case. Stela Dimitrova, Clinic of Hematology, University Hospital St Marina – Varna, Bulgarian Society of Hematology

BCR-ABL1(+) ALL – blast transformation or de novo acute leukemia in a JAK2 V617F(+) MPN patient. Yanitza Davidkova, Laboratory of Hematopathology and Immunology, National Specialised Hematology Hospital, Bulgarian Society of Hematology

17:00 – 17:20 Coffee Break

Pravets Conference Hall

17:20 – 19:30 Satellite symposia

17:20 – 17:30 Satellite symposium Abbvie:

CLL treatment with Venetoclax - UMHAT “St. Marina”, Varna experience
Stela Dimitrova

17:30 – 18:30 Satellite symposium Pfizer:

Is it possible to change the outlook in acute leukemias: complex treatment decisions in the era of new therapies?

Moderator: Margarita Guenova

When the innovations meet the patients' needs with R/R ALL – predefining the long-term results. Prof. Guido Kobbe, Department of Hematology, Oncology and Clinical Immunology, University Hospital of Dusseldorf, Germany

Unmet medical need in de novo treatment of AML. Prof. Arnon Nagler, Chair Acute Leukemia working party, European Society of Blood and Marrow Transplantation (EBMT); Director, Hematology Division, Chaim Sheba Medical Center, Israel

18:30 – 19:30 Satellite symposium Amgen: Amgen in Hematology - Present and Look into the Future.

20:00 – 22:00 Dinner / The Lake Resturant/

October 12, 2019 /Saturday/

SCIENTIFIC PROGRAM

Pravets Conference Hall

08:30 – 9:50 Educational session – Meet the experts

Chairs: Evgueniy Hadjiev, Georgi Arnaudov

08:30 – 08:50 The role of the neighbor genes JARID2 and DTNBP1 in the genomic changes in schizophrenia, carcinogenesis in Wiskott-Aldrich syndrome and pathogenesis of myeloproliferative disorders with 6p-anomaly
Mitev L.

08:50 – 09:10 Hemostasis – research of today is tomorrow’s innovation
Grudeva-Popova Zh.

09:10 – 09:30 Modern treatment of multiple myeloma in relapsed and refractory patients. Can we pay the price?
Goranova-Marinova V., Goranov St.

09:30 – 09:50 Chronic lymphocytic leukemia: new drugs change the therapeutic landscape and turn chemotherapeutical regimens into historical
Goranov St., Goranova-Marinova V.

09:50 – 11:00 Satellite symposia

09:50 – 10:00 Satellite symposium Abbvie:

CLL therapy with Venetoclax – the experience of University Hospital Sv.Ivan Rilski. Tanya Popova

10:00 – 11:00 Satellite symposium Novartis:

Rydapt: the myth in AML comes to reality

Moderator: Zhanet Grudeva-Popova

11:00 – 11:30 Coffee Break

11:30 – 13:30 Scientific session 1: Lymphoid and plasma cell neoplasms

Chairs: Zhanet Grudeva-Popova, Stefan Goranov, Maya Yordanova

11:30 – 11:45 Therapeutic challenges in patients with relapsed/refractory Hodgkin lymphoma treated in NSHATHD

Venkov K., Staneva M., Krysteva K, Arnaudov G., Ganeva P., Petrov Y., Stoyanova Zh., Balatzenko G., Guenova M., Spassov B.

11:45 – 12:00 Analysis of prognosis and therapeutic outcome of patients with Hodgkin lymphoma for a five years period. Role of interim PET/CT in treatment approach optimization

Shemelekova L., Hadjiev E., Tsvetkova G., Vasileva Tsv., Bekirova E., Raikovska M., Teneva I., Taneva V., Hristova Sv., Hadjiiska V.

12:00 – 12:15 Prognostic factors influencing outcome after therapy with Brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma

Goranova-Marinova V., Ignatova K., Ganeva P., Spasov E., Arnaudov G., Micheva I.,

Gercheva L., Radinov A., Petrova R., Tsvetkova N., Hadzhiev E., Bogdanov L., Tsvetkov N., Spassov B., Grudeva-Popova Zh.

12:15 – 12:30 Impact of clonal heterogeneity in complex karyotypes of multiple myeloma patients on first line Bortezomib-based therapy: a single-institution experience in Bulgaria

Angelova S., Ignatova K., Ganeva P., Lozenov St., Jagurinoski M., Balatzenko G., Spassov B.

12:30 – 12:45 Clinical characteristics and therapeutic results in 22 patients with hairy cell leukemia

Hadjiev E., Tsvetkova G., Shemelekova L., Nikolova Tsv., Hristova S.

12:45 – 13:00 Immunophenotypic and clinical correlations in indolent B-cell lymphoid neoplasms with leukemic presentation

Davidkova Y., Vladimirova R., Madzharova V., Muhtarova M., Jagurinoski M., Stoeva V., Spassov B., Balatzenko G., Guenova M.

13:00 – 13:15 Prognostic significance of the most frequent molecular anomalies in pediatric acute lymphoblastic leukemia

Yurukova N., Balatzenko G., Avramova B., Yordanova M., Buchvarov B., Konstantinov D.

13:15 – 13:30 Evaluation of galactomannan test for the diagnosis of invasive aspergillosis in patients with hematological malignancies

Niqzi D., Stoeva T., Atanasova S., Reznik I., Micheva I.

13:30 – 14:15 Lunch / Ezeroto Main Restaurant/

14:15 – 16:50 Scientific session 2: Hematopoietic stem cell transplantation and Myeloid leukemias

Chairs: Ilina Micheva, Boryana Avramova, Branimir Spassov

14:15 – 14:30 Acute and chronic GVHD. Analysis of the results of conducted allogeneic hemopoetic stem cell transplantations in the Specialized Hospital for Active Treatment of Hematological Diseases

Ganeva P., Milcheva K., Tonev I., Dikov T., Nasseva E., Mincheff M., Guenova M., Spassov B., Arnaudov G.

14:30 – 14:45 CMV and EBV reactivation after allogeneic hemopoetic stem cell transplantations

Milcheva K., Ganeva P., Aleksandrova D., Ilin D., Nasseva E., Tonev I., Spassov B., Arnaudov G.

14:45 – 15:00 Analysis of the results of conducted allogeneic hemopoetic stem cell transplantations in the Specialized Hospital for Active Treatment of Hematological Diseases

Ganeva P., Milcheva K., Tonev I., Simeonov S., Angelova S., Nasseva E., Mincheff M., Balatzenko G., Guenova M., Spassov B., Arnaudov G.

15:00 – 15:15 The aspect of Non-medical care for patients with bone marrow transplantation - our experience

Donkina V., Milcheva K., Ganeva P., Arnaudov G., Spassov B.

15:15 – 15:25 The path of apheresis platelet concentrate from the donor to the recipient - the experience of the Center of Transfusion Hematology, Military

Medical Academy - Sofia in preparing quality blood components

Terzieva K., Grancharova E., Popov R., Kindekov I.

15:25 – 15:40 Results of therapy with BFM protocols in children and adolescents with AML – 10 years experience

Avramova B., Yordanova M., Kaleva V., Spasova M., Bachvarov K., Yurukova N., Belcheva M., Burnusuzov H., Spasov N., Peteva E., Vlahova I., Hristova T., Konstantinov D.

15:40 – 15:55 Prognostic relevance of the variants of PML-RARA fusion transcripts and FLT3-ITD status in acute promyelocytic leukemia

Balatzenko G., Ivanova S., Spassov B., Ganeva P., Arnaudov G., Stoeva V., Ignatova K., Donchev M., Yankova T., Popova-Grudeva Zh., Stojchov-Jagurinoska M., Hadjiev E., Tsvetkova G., Madzharova V., Jagurinoski M., Davidkova Y., Guenova M.

15:55 – 16:10 Pediatric acute promyelocytic leukemia

Vlahova I., Yordanova M., Avramova B., Balatzenko G., Yurukova N., Nuhova S., Buchvarov K., Hristova T., Banchev At., Stoyanova D., Konstantinov D.

16:10 – 16:20 Association of cellular immunity with molecular response in chronic myeloid leukemia patients on tyrosine kinase inhibitors therapy

Jagurinoski M., Stojchov-Jagurinoska M., Vladimirova R., Muhtarova M., Davidkova Y., Madzharova V., Ivanova S., Stoyanova Zh., Spassov B., Balatzenko G., Guenova M.

16:20 – 16:35 Pediatric chronic myeloid leukemia – experience of the Bulgarian pediatric clinics in Bulgaria

Yordanova M., Vlahova I., Balatzenko G., Avramova B., Buchvarov K., Yurukova N., Hristova T., Chakurov I., Banchev At., Stoyanova D., Konstantinov D.

16:35 – 16:50 A retrospective study of the therapeutic options and results in patients with intermediate-2 and high risk MDS in the national hematology hospital

Nikolova V., Simonoski N., Aleksov E., Jagurinoski M., Angelova S., Balatzenko G., Ganeva P., Guenova M., Ignatova K., Donchev M., Arnaudov G., Spassov B.

16:50 – 17:10 Coffee Break

Tera Conference Hall

17:10 – 18:00 Scientific session 3: Myeloproliferative neoplasms

Chairs: Liana Gercheva, Gueorgui Balatzenko

17:10 – 17:23 Inflammatory cytokines in patients with Philadelphia-negative myeloproliferative neoplasms – pilot test results, clinical and laboratory correlations

Tsvetkova G., Hadjiev E., Kandilarova S., Naumova E., Shemelekova L., Vasileva Tsv., Raykovska M., Bekirova E., Hristova S.

17:23 – 17:36 The role of hepcidin and dysregulated iron homeostasis in the pathogenesis of anemia in myelofibrosis

Dimitrova St., Micheva I., Gerova D., Gercheva L.

17:36 – 17:48 Identification of HLA class I protective alleles for development of JAK2 V617F driven myeloproliferative neoplasms

Ivanova M., Tsvetkova G., Lukanov Tz., Alhadra B., Stoimenova A., Hadjiev E., Shivarov V.

17:48 – 18:00 Monitoring of the clinical characteristics and therapeutic efficacy in newly diagnosed patients with primary immune thrombocytopenia for a 5 year period

Vasileva Tsv., Tsvetkova G., Shemelekova L., Raykovska M., Bekirova E., Minchev I., Hadjiev E.

18:00 – 19:00 Satellite symposium

18:00 – 19:00 Satellite symposium Genesis Pharma:

Vidaza Today - effective management of higher-risk MDS and AML. Experience exchange across the Balkans.

Moderator: Gueorgui Balatzenko

Outcome after Azacitidine treatment in patients with HR MDS and AML – a multicenter Bulgarian experience. Assoc.Prof. Iliana Micheva, Hematology Clinic, University Hospital St.Marina – Varna

Greek MDS Registry: Questions and answer from real world experience on treatment with Azacytidine of 1200 patients. Prof. Argiris Symeonidis, Head of Hematology Division and Stem Cell Transplantation Unit, Department of Internal Medicine, Medical School – University of Patras, President of the Hellenic MDS Study Group, Director of the Hellenic National MDS Registry, Greece

**October 12, 2019 /Saturday/
NURSES' SESSION: BEST PRACTICES**

Tera Conference Hall

11:30 – 13:30 Nurses' session 1

Chairs: Julian Raynov, Dimitrina Bacheva

11:30 – 11:45 How to improve the quality of life of patients with coagulopathies
Georgieva H.

11:45 – 12:00 Therapeutic behavior in patients with recurrent multiple myeloma. Focus on new drugs and combinations in our reality
Nenkova E., Yordanova A., Temelakieva E.

12:00 – 12:15 Immunotherapy in ALL. The use of Blinatumumab in clinical practice
Eyub S., Milcheva K.

12:15 – 12:30 Nursing practices in the diagnosis, treatment and follow-up of patients with CMV infection
Kitanova D.

12:30 – 12:45 What is important to know about Gazyvaro administration and the behavior related to infusion reactions?
Pandarska L.

12:45 – 13:00 Risks in hematology infusion therapy
Mitova Sv.

13:00 – 13:15 Competencies and behavior of nurses for port catheter management in patients on chemotherapy

Krasteva D.

13:15 – 13:30 Challenges to healthcare professionals in fulfilling nursing responsibilities for patients with benign and malignant hematologic diseases undergoing outpatient therapy

Petrova M.

13:30 – 14:15 Lunch /Ezeroto Main Restaurant/

14:15 – 16:00 Nurses' session 2

Chairs: Julian Raynov, Angelina Vasileva

14:15 – 14:30 Feedback: Patients' satisfaction with the quality of health care at NSHATHD

Mileva K.

14:30 – 14:45 The nurse – a coordinator in the follow-up of patients with myelofibrosis

Mitova S., Yumerova A.

14:45 – 15:00 Chronic myeloid leukemia (CML) - treatment free remission (TFR). Real-life patient care

Vandova Gr., Hajdiev E. Tsvetkova G.

15:00 – 15:15 About facing the diagnosis and how to deal with the disease. The patient's point of view

A discussion with a CML patient

15:15 – 15:30 Quality of life and socio-medical problems in patients with malignant hematological disorders - studies and surveys

Trohleva S., Milanova I.

15:30 – 15:45 Saturation of nursing care with psychological support

Bacheva D.

15:45 – 16:00 General discussion

16:50 – 17:10 Coffee break

October 12, 2019 /Saturday/

SCIENTIFIC PROGRAM

Poster area

19:00 – 20:00 Poster session – lobby Pravets Conference Hall

Chairs: Valeria Kaleva, Veselina Goranova-Marinova, Milcho Mincheff

20:30 – 24:00 Dinner /Pravets Hall/

October 13, 2019 /Sunday/

GENERAL ASSEMBLY

Pravets Conference Hall

Posters:

Myeloid neoplasms

- 1. Two cases with acute myeloblastic leukemia and trisomy of chromosome 4**
Yavorova A., Asenova A., Grahlyova L., Mitev L.
- 2. Two cases of acute myeloblastic leukemia and der (1;15) (p10;q10)**
Mitev L., Grahlyova L., Yavorova A., Asenova A.
- 3. Clinical case of CML-patient with complex karyotype – assessment of therapeutic response and prognosis**
Yavorova A., Yordanov A., Hrishev V., Markova M., Damyanova V., Nikolova D., Mitev L.
- 4. A case of chronic myeloid leukemia following kidney**
Markova M., Hrishev V.
- 5. Pregnancy and CML - clinical case and discussion**
Bogdanov L., Slavcheva V., Hristov I., Todorieva D., Tzvetkov N., Balatzenko G.
- 6. Chronic myeloid leukaemia first presenting as a megakaryocytic blast crisis – a case report**
Yankova V., Milcheva K., Donchev M., Yankova T., Arnaudov G., Guenova M., Balatzenko G., Spassov B.
- 7. Concomitant presentation of a t-acute myeloid leukemia and a late relapse of multiple myeloma after autologous haematopoietic stem cell transplantation**
Yankova V., Milcheva K., Donchev M., Stojchov-Jadurinoska M., Jagurinoski M., Balatzenko G., Arnaudov G., Guenova M., Spassov B.
- 8. Overexpression of PRV1 gene in myeloid neoplasms and association with other molecular abnormalities**
Stoeva V., Balatzenko G., Ivanova S., Spassov B.
- 9. 3-year experience of some Bulgarian centers in the treatment of myelofibrosis with Ruxolitinib**
Todorieva D., Grudeva-Popova Zh., Tsvetkov N., Gercheva L., Micheva I., Dimitrova S., Beleva E., Ivanova H., Slavcheva V., Bogdanov L., Hristov I.
- 10. Long-Range Movement of JAK2 Gene in Interphase Nucleus**
Mitev L.
- 11. Molecular cytogenetic study in essential thrombocythaemia**
Grahlyova L., Asenova A., Mitev L.
- 12. Chronic myelomonocytic leukemia and monocytosis in myeloproliferative neoplasms – clinical and molecular correlations**
Davidkova Y., Jagurinoski M., Spassov B., Balatzenko G., Guenova M.

Lymphoid and plasma cell neoplasms

- 13. Diagnostic role of conventional cytogenetics and fluorescent in situ hybridization in a patient with chronic lymphocytic leukemia (case report)**
Miteva V., Ruseva C., Varbanov H., Micheva I., Angelova L.
- 14. A rare case of intravascular diffuse B-cell lymphoma with extranodal involvement of the kidneys, adrenal glands and brain**
Georgieva D., Amin I., Raykov D.
- 15. Flow cytometry of cerebrospinal fluid is complementary to cytomorphology in the evaluation of hematologic malignancies**
Vladimirova R., Muhtarova M., Davidkova Y., Madzharova V., Jagurinoski M., Guenova M.

16. A case of diffuse large B-cell non Hodgkin lymphoma with infiltration of maxillary sinus

Raykovska M., Hadjiev E., Shemelekova L., Tsvetkova G., Vasileva Tsv., Bekirova E., Taneva V., Teneva I.

17. Application of radiosurgery with cyberknife in the treatment of lymphoma of an eyeball

Popov V., Graklanov V., Vlaykova M., Mihova L., Grudeva-Popova Zh.

18. Indolent non Hodgkin's lymphomas with central nervous system involvement

Nenova I., Beleva E., Georgieva A., Graklanov V., Grudeva-Popova Zh.

19. Hemophagocytic lymphohistiocytosis in adults – is it important to recognize it?

Georgieva A., Nenova I., Beleva E.

20. Histological transformation to diffuse large B-cell Lymphoma in a patient with Waldenström macroglobulinemia

Teneva I., Hadjiev E., Shemelekova L., Tsvetkova G., Vasileva Tsv., Bekirova E., Taneva V.

21. Lymphoid neoplasias associated with IgM paraprotein

Gartcheva L., Davidkova Y., Dimitrova K., Petkova V., Vladimirova R., Muhtarova M., Madzharova V., Spassov B., Guenova M.

22. Difficulties in identifying biclonal multiple myelomas

Gartcheva L., Petkova V., Dimitrova K., Ganeva P., Guenova M., Spassov B.

23. POEMS syndrome - a diagnostic challenge

Lukanov R., Micheva I., Antonov A., Varbanov H., Bochev P.

24. Extramedullary relapse of multiple myeloma - aggressive manifestation and multi-drug resistance

Bekirova E., Tsvetkova G., Shemelekova L., Vasileva Tsv., Raykovska M., Teneva I., Hadjiev E., Hadjiiska V., Hristova S.

25. Epidemiological profile of patients with multiple myeloma, diagnosed and treated in the Specialized Hospital for Active Treatment of Hematological Diseases

Milcheva K., Avramova V., Jagurinoski M., Stojchov-Jagurinoska M., Ignatova K., Donchev M., Angelova S., Arnaudov G., Balatzenko G., Guenova M., Spassov B.

26. Multiparameter flow cytometry in the diagnosis of plasma cell disorders

Stoyanov N., Dikov T., Ganeva P., Muhtarova M., Yancheva T., Guenova M.

27. Monoclonal gammopathy with renal significance (MGRS) or when MGUS is no longer undetermined and should be treated ...

Goranov St., Goranova-Marinova V.

Hematopoietic stem cell transplantation

28. Transfusion risk and pharmacoeconomic assessment at allogeneic hematopoietic stem cells transplantation

Lazarova Y., Ivanova Sv., Arnaudov G., Ganeva P., Milcheva K., Mincheff M., Tonev I., Spassov B.

29. Treatment of steroid-refractory chronic graft vs host disease (cGVHD) using extracorporeal photopheresis (ECP), including transfusions of frozen photopheresis products – a case report

Mincheff M., Ganeva P., Tonev I., Botev Ts., Simeonov S., Spassov B.

30. Influence of the extracellular cryoprotectants in hematopoietic stem cell freezing

Tonev I., Simeonov S., Hristova S., Miteva M., Mitkov I., Mincheff M.

31. Histopathology in the differential diagnosis of GVHD

Dikov T., Stoyanov N., Ganeva P., Arnaudov G., Guenova M.

Varia

32. Analysis of nosocomial infections in the Specialized Hospital for Active Treatment of Hematological Diseases, etiology and selected antibiotic resistance

Borissova M., Yossifov Y. Y., Popova E., Mitkov I., Mineva B.

33. Invasive fungal infections in children with acute leukemia: 10 years of experience at the Clinic for Pediatric Clinical Hematology and Oncology, University Hospital "St. Marina" - Varna

Nuhova S., Hristozova Hr., Belcheva M., Peteva E., Marinska B., Petrova Ch., Shirokova K., Niyazi D., Stoeva T., Kaleva V.

34. Clostridium Difficile infections in children with cancer

Xristozova Hh., Petrova Ch., Belcheva M., Marinska B., Peteva E., Nukhova S., Shirokova K., Kamenova V., Stoeva T., Kaleva V.

35. Plasticizers and their effect on human health

Grancharova E., Terzieva K., Kindekov I.

36. A case of supportive therapy with platelet concentrates in a T-cell lymphoblastic lymphoma patient with thrombocytopenia after chemotherapy

Terzieva K., Grancharova E., Kindekov I., Popov R.

37. BMI – A Defining Factor for Joint Health in Haemophilia Patients

Banchev At., Stoyanova D., Kaleva V., Peteva El., Ignatova Ig., Kostova Sv., Penkova D., Konstantinov D.

38. Analysis of the bone mineral density in adult Bulgarian patients with transfusion-dependent beta thalassemia in the era of transfusion and chelating therapy

Sapunarova K., Goranova-Marinova V., Deneva T., Tsvetkova S., Georgiev P., Grudeva-Popova Zh.

39. Serum sclerostin levels - associations with bone mineral density, markers of bone metabolism and thalassaemia - spessific characteristics in adult patients with transfusion-dependent beta thalassaemia

Sapunarova K., Goranova-Marinova V., Georgiev P. Deneva T., Tsvetkova S., Grudeva-Popova Zh.